Laureate signs antibody deal with Tolera
This article was originally published in Scrip
Executive Summary
Laureate Pharma has signed a contract manufacturing agreement for Tolera Therapeutics' TOL101 monoclonal antibody under cGMP conditions to be used in clinical trials. TOL101 has demonstrated safety and efficacy in Phase I and II trails for treating episodes of rejection or as a means of preventing rejection in kidney and other solid organ transplants. Laureate, a biopharmaceutical development and protein production company, and Tolera, a biotechnology company, are both based in the US.